Salix Pharmaceuticals, Ltd. Announces Early Termination Of HSR Waiting Period For Pending Transaction

RALEIGH, N.C.--(BUSINESS WIRE)--Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) today announced that it has received notice of the early termination of the waiting period for U.S. antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, relating to its previously announced combination transaction with Cosmo Pharmaceuticals S.p.A. (SIX: COPN). The waiting period was scheduled to expire on August 21, 2014. Termination of the waiting period satisfies a condition to the closing of the transaction. Completion of the transaction remains subject to approval by Salix’s stockholders and certain other closing conditions.

Help employers find you! Check out all the jobs and post your resume.